Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bimekizumab versus Adalimumab in Plaque Psoriasis
Richard B. Warren, Andrew Blauvelt, Jerry Bagel, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 2, pp. 130-141
Open Access | Times Cited: 168

Showing 26-50 of 168 citing articles:

Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
Bruce Strober, C. Paul, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 3, pp. 486-495
Open Access | Times Cited: 21
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial
Diamant Thaçi, Ronald Vender, Menno A. de Rie, et al.
British Journal of Dermatology (2023) Vol. 188, Iss. 1, pp. 22-31
Open Access | Times Cited: 19
Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis
April W. Armstrong, Richard B. Warren, Yichen Zhong, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 11, pp. 2839-2857
Open Access | Times Cited: 19
Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease
Suzanne Cole, Avneet Manghera, Lachrissa A. Burns, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 152, Iss. 3, pp. 783-798
Closed Access | Times Cited: 18
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials
Kenneth B. Gordon, Richard Langley, Richard B. Warren, et al.
British Journal of Dermatology (2023) Vol. 190, Iss. 4, pp. 477-485
Open Access | Times Cited: 18
IL-17: Balancing Protective Immunity and Pathogenesis
Lu Sun, Lufei Wang, Bethany B. Moore, et al.
Journal of Immunology Research (2023) Vol. 2023, pp. 1-9
Open Access | Times Cited: 17
Dual inhibition of IL-17A and IL-17F in psoriatic disease
Helena Iznardo, L. Puig
Therapeutic Advances in Chronic Disease (2021) Vol. 12
Open Access | Times Cited: 38
Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, et al.
Dermatology and Therapy (2021) Vol. 12, Iss. 1, pp. 167-184
Open Access | Times Cited: 38
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
Ali Al‐Janabi, Z.Z.N. Yiu
Psoriasis Targets and Therapy (2022) Vol. Volume 12, pp. 1-14
Open Access | Times Cited: 26
English version of Japanese guidance for use of biologics for psoriasis (the 2022 version)
Hidehisa Saeki, Tomotaka Mabuchi, Akihiko Asahina, et al.
The Journal of Dermatology (2022) Vol. 50, Iss. 2
Open Access | Times Cited: 25
Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study
Xenofon Baraliakos, Atul Deodhar, Maxime Dougados, et al.
Arthritis & Rheumatology (2022) Vol. 74, Iss. 12, pp. 1943-1958
Open Access | Times Cited: 24
Exploring the association and causal effect between white blood cells and psoriasis using large-scale population data
Guowei Zhou, Xiangmei Ren, Zhenwei Tang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis
Philip J. Mease, Dafna D. Gladman, Joseph F. Merola, et al.
Lara D. Veeken (2024) Vol. 63, Iss. 7, pp. 1779-1789
Open Access | Times Cited: 5
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
Joshua Burshtein, Milaan Shah, Danny Zakria, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 2, pp. 323-339
Open Access | Times Cited: 5
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study
Alexander Rimke, Siddhartha Sood, Brian D. Rankin, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 2, pp. 359-361
Closed Access | Times Cited: 5
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective study
Siddhartha Sood, Alexander Rimke, Brian D. Rankin, et al.
Journal of the American Academy of Dermatology (2024)
Closed Access | Times Cited: 5
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis
Matthias Augustin, Alice B. Gottlieb, Mark Lebwohl, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 10, pp. 2841-2857
Open Access | Times Cited: 5
Current therapeutic overview and future perspectives regarding the treatment of psoriasis
Francesco Ferrara, Chiara Verduci, Emanuela Laconi, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113388-113388
Closed Access | Times Cited: 5
Bimekizumab for the Treatment of Psoriasis
Egídio Freitas, Andrew Blauvelt, Tiago Torres
Drugs (2021) Vol. 81, Iss. 15, pp. 1751-1762
Closed Access | Times Cited: 30
Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety
Frank Kolbinger, Franco Di Padova, Atul Deodhar, et al.
Pharmacology & Therapeutics (2021) Vol. 229, pp. 107925-107925
Open Access | Times Cited: 28
Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases
Mark David Andrews, Kevin N. Dack, Marcel J. de Groot, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 8828-8842
Closed Access | Times Cited: 20
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
Georgios Kokolakis, Richard B. Warren, Bruce Strober, et al.
British Journal of Dermatology (2022) Vol. 188, Iss. 3, pp. 330-340
Closed Access | Times Cited: 20
Biomarkers and biologics related with psoriasis and psoriatic arthritis
Weize Gao, Zhan Wang, Wenshuai Li, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110646-110646
Closed Access | Times Cited: 13
Nail psoriasis and nail lichen planus: Updates on diagnosis and management
Jonathan K. Hwang, Chander Grover, Matilde Iorizzo, et al.
Journal of the American Academy of Dermatology (2023) Vol. 90, Iss. 3, pp. 585-596
Closed Access | Times Cited: 13
Targeted Therapies in Psoriatic Arthritis—An Update
Sonia Sundanum, Carl Orr, Douglas J. Veale
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6384-6384
Open Access | Times Cited: 12

Scroll to top